Ivania Rizo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ivania Rizo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aya Bassatne
Section of Endocrinology Diabetes and Nutrition, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine , Boston, MA 02118
2 shared publications - Kathryn L. Fantasia
Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
2 shared publications - Alejandro Campos
Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine Mayo Clinic Rochester Minnesota USA
1 shared publication Caroline M. Apovian
Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University School of Medicine and Boston Medical Center, Boston, MA, United States
1 shared publicationChristopher Lee
Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
1 shared publicationColin Pierce
1 shared publication
Latest Publications
- 14 July 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (11) , e2327-e2346
Medical treatments for obesity: what does the future have in store?
Context: Obesity is a chronic relapsing disease associated with substantial morbidity, mortality, and health care costs. Contemporary obesity pharmacotherapies extend beyond weight reduction, with evidence for improvements across multiple obesity-related complications, supporting a shift toward phenotype-guided, complication-centric care. Evidence Acquisition: A systematic literature search of the Medline database using MeSH terms and keywords related to new-generation obesity pharmacotherapy was conducted to identify articles published between 2021 and 2026. Reference lists of relevant reviews were screened to identify additional eligible studies. Phase 2 and 3 clinical trials evaluating emerging obesity pharmacotherapies in adults and reporting outcomes, including weight loss and obesity-related complications, were included. Evidence Synthesis: Entero-pancreatic hormone-based therapies targeting glucagon-Like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, amylin, and glucagon pathways demonstrate substantial efficacy beyond weight reduction. These hormones act through complementary mechanisms regulating appetite, energy balance, and metabolic homeostasis. GLP-1 based agents achieve approximately 10-15% weight loss, whereas agents targeting multiple pathways demonstrate greater efficacy. Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20% and the triple agonist retatrutide produced reductions exceeding 25%. Beyond weight loss, these agents improve glycemia, support diabetes prevention, and produce organ-specific benefits, including reduced cardiovascular events, improved heart failure symptoms, decreased obstructive sleep apnea severity, improvement of metabolic dysfunction-associated steatohepatitis, slowing chronic kidney disease progression, and reduced osteoarthritis-related pain. Conclusion: Next-generation obesity pharmacotherapies represent a major advance in obesity management and support a treat-to-target approach prioritizing improvement in obesity-related complications and metabolic health. Effective implementation will require individualized therapy and attention to long-term safety, access, and equitable delivery of care.
- 14 July 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (11) , e2327-e2346
Medical treatments for obesity: what does the future have in store?
Context: Obesity is a chronic relapsing disease associated with substantial morbidity, mortality, and health care costs. Contemporary obesity pharmacotherapies extend beyond weight reduction, with evidence for improvements across multiple obesity-related complications, supporting a shift toward phenotype-guided, complication-centric care. Evidence Acquisition: A systematic literature search of the Medline database using MeSH terms and keywords related to new-generation obesity pharmacotherapy was conducted to identify articles published between 2021 and 2026. Reference lists of relevant reviews were screened to identify additional eligible studies. Phase 2 and 3 clinical trials evaluating emerging obesity pharmacotherapies in adults and reporting outcomes, including weight loss and obesity-related complications, were included. Evidence Synthesis: Entero-pancreatic hormone-based therapies targeting glucagon-Like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, amylin, and glucagon pathways demonstrate substantial efficacy beyond weight reduction. These hormones act through complementary mechanisms regulating appetite, energy balance, and metabolic homeostasis. GLP-1 based agents achieve approximately 10-15% weight loss, whereas agents targeting multiple pathways demonstrate greater efficacy. Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20% and the triple agonist retatrutide produced reductions exceeding 25%. Beyond weight loss, these agents improve glycemia, support diabetes prevention, and produce organ-specific benefits, including reduced cardiovascular events, improved heart failure symptoms, decreased obstructive sleep apnea severity, improvement of metabolic dysfunction-associated steatohepatitis, slowing chronic kidney disease progression, and reduced osteoarthritis-related pain. Conclusion: Next-generation obesity pharmacotherapies represent a major advance in obesity management and support a treat-to-target approach prioritizing improvement in obesity-related complications and metabolic health. Effective implementation will require individualized therapy and attention to long-term safety, access, and equitable delivery of care.
- Open Access
- 9 April 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (6) , 2387-2407
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Obesity remains a major global health challenge with increasing prevalence rates despite decades of long-standing efforts focused on lifestyle interventions, pharmacotherapy, and surgery. The rapid development of highly effective incretin-based therapies has transformed obesity care by achieving clinically significant and substantial weight loss. Building on this success, an expanding therapeutic pipeline—including dual and triple agonists, amylin analogues, and other multimodal agents—targets complementary pathways and more closely aligns treatment with the biological complexity of obesity. Together, these advancements offer a promising future for long-term, sustainable obesity management and may help shift population-level trends. This review summarizes current evidence from published trials on the mechanisms, efficacy, and safety of approved and investigational medications, and highlights the potential impact of these therapies on the evolving landscape of obesity care.
- 9 April 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (6) , 2387-2407
Open AccessFuture Directions in the Medical Treatment of Obesity: A Narrative Review
Obesity remains a major global health challenge with increasing prevalence rates despite decades of long-standing efforts focused on lifestyle interventions, pharmacotherapy, and surgery. The rapid development of highly effective incretin-based therapies has transformed obesity care by achieving clinically significant and substantial weight loss. Building on this success, an expanding therapeutic pipeline—including dual and triple agonists, amylin analogues, and other multimodal agents—targets complementary pathways and more closely aligns treatment with the biological complexity of obesity. Together, these advancements offer a promising future for long-term, sustainable obesity management and may help shift population-level trends. This review summarizes current evidence from published trials on the mechanisms, efficacy, and safety of approved and investigational medications, and highlights the potential impact of these therapies on the evolving landscape of obesity care.
- Open Access
- 6 June 2025
- Published by Elsevier in Obesity Pillars
- Vol. 15, 100185
Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system
- 6 June 2025
- Published by Elsevier in Obesity Pillars
- Vol. 15, 100185
Open AccessKnowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system
- 5 January 2024
- Published by Journal of Case Reports in Journal of Case Reports
- Vol. 14 (1) , 1-4
Ectopic Cushing Syndrome Secondary to Metastatic Small Cell Carcinoma of Unknown Primary: A Multidisciplinary Approach
Home Page right<div style="disp
- 5 January 2024
- Published by Journal of Case Reports in Journal of Case Reports
- Vol. 14 (1) , 1-4
Ectopic Cushing Syndrome Secondary to Metastatic Small Cell Carcinoma of Unknown Primary: A Multidisciplinary Approach
Home Page right<div style="disp
- 1 January 2023
- Published by Springer Nature
- p. 323-335
Diabetes After Bariatric Surgery
- 10 March 2021
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 15 (5) , 1010-1017
Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital
Limited data exist regarding diabetes technology use among adults with type 1 diabetes (T1D) in urban racially/ethnically diverse safety-net hospitals. We examined racial/ethnic differences in the use of continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) in this setting. A retrospective review of 227 patients ≥ 18 years of age with T1D seen in an urban, safety-net endocrinology clinic during 2016-2017 was completed (mean age: 39; 80% English-speaking; 50% had public insurance). Diabetes technology use, defined as either CGM or CSII or both CGM and CSII, and clinical outcomes were examined by race/ethnicity. Overall, 30% used CGM and 26% used CSII. After adjusting for age, language, insurance, and annual income, diabetes technology use in non-White patients was significantly lower than in White patients, predominantly lower in Black (aOR 0.25 [95% CI 0.11-0.56]) and patients identified as other race/ethnicity (aOR 0.30 [95% CI 0.11-0.77]). At the highest household income level (≥$75,000/y), Black and Hispanic individuals were significantly less likely than White individuals to use diabetes technology (P < .0007). Mean hemoglobin A1c (HbA1c) was lower in patients using any diabetes technology compared with patients using no technology (P < .0001). Use of CGM and CSII together was associated with the lowest HbA1c across all racial/ethnic groups. Racial/ethnic disparities in diabetes technology use and glycemic control were observed even after adjusting for sociodemographic factors. Further research should explore barriers to accessing diabetes technology in non-White populations.
- 10 March 2021
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 15 (5) , 1010-1017
Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital
Limited data exist regarding diabetes technology use among adults with type 1 diabetes (T1D) in urban racially/ethnically diverse safety-net hospitals. We examined racial/ethnic differences in the use of continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) in this setting. A retrospective review of 227 patients ≥ 18 years of age with T1D seen in an urban, safety-net endocrinology clinic during 2016-2017 was completed (mean age: 39; 80% English-speaking; 50% had public insurance). Diabetes technology use, defined as either CGM or CSII or both CGM and CSII, and clinical outcomes were examined by race/ethnicity. Overall, 30% used CGM and 26% used CSII. After adjusting for age, language, insurance, and annual income, diabetes technology use in non-White patients was significantly lower than in White patients, predominantly lower in Black (aOR 0.25 [95% CI 0.11-0.56]) and patients identified as other race/ethnicity (aOR 0.30 [95% CI 0.11-0.77]). At the highest household income level (≥$75,000/y), Black and Hispanic individuals were significantly less likely than White individuals to use diabetes technology (P < .0007). Mean hemoglobin A1c (HbA1c) was lower in patients using any diabetes technology compared with patients using no technology (P < .0001). Use of CGM and CSII together was associated with the lowest HbA1c across all racial/ethnic groups. Racial/ethnic disparities in diabetes technology use and glycemic control were observed even after adjusting for sociodemographic factors. Further research should explore barriers to accessing diabetes technology in non-White populations.
- 23 May 2019
- Published by Springer Nature in Current Obesity Reports
- Vol. 8 (3) , 284-291
Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).
- 23 May 2019
- Published by Springer Nature in Current Obesity Reports
- Vol. 8 (3) , 284-291
Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).
- Open Access
- 15 January 2019
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 812
Diabetic Ketoacidosis Post Bariatric Surgery
In patients with type 2 diabetes, bariatric surgery can lead to significant improvements in glycemic control and diabetes remission. We present a case of a Hispanic female with type 2 diabetes phenotype who underwent bariatric surgery and post-operatively stopped her insulin therapy due to multiple reasons, including decreased oral intake and concern for hypoglycemia. Ultimately, she developed diabetic ketoacidosis. She does not fit into the classical type 2 diabetes or type 1 diabetes definition but into the heterogeneous subgroup of diabetes called ketosis-prone diabetes.
- 15 January 2019
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 812
Open AccessDiabetic Ketoacidosis Post Bariatric Surgery
In patients with type 2 diabetes, bariatric surgery can lead to significant improvements in glycemic control and diabetes remission. We present a case of a Hispanic female with type 2 diabetes phenotype who underwent bariatric surgery and post-operatively stopped her insulin therapy due to multiple reasons, including decreased oral intake and concern for hypoglycemia. Ultimately, she developed diabetic ketoacidosis. She does not fit into the classical type 2 diabetes or type 1 diabetes definition but into the heterogeneous subgroup of diabetes called ketosis-prone diabetes.